- Home
- NXPL vs JSPR Comparison
NXPL vs JSPR Comparison
Compare NXPL & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXPL | JSPR |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 26.3M |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NXPL | JSPR |
|---|---|---|
| Price | $9.08 | $0.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 10.5K | ★ 359.5K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | 19.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,869,558.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.50 | N/A |
| 52 Week Low | $0.34 | $0.32 |
| 52 Week High | $9.94 | $2.69 |
Technical Indicators
Market Signals| Indicator | NXPL | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 41.28 |
| Support Level | $8.65 | $0.55 |
| Resistance Level | $9.91 | $0.60 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 48.98 | 16.64 |
Price Performance
Historical ComparisonAbout NXPL NextPlat Corp
NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.